Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil (BRAVE)

Latin American Cooperative Oncology Group (LACOG)

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT05034393

LACOG 0221

Details and patient eligibility

About

This study aims to describe in detail the patient journey from diagnosis to the beginning of treatment and patterns of care of hormone receptor- positive, HER2-negative de novo or recurrent metastatic breast cancer between January 2018 and December 2020 in Brazil.

Enrollment: 308 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women ≥18 years old
• Histologically confirmed hormone receptor-positive HER2-negative invasive breast cancer
• Hormone receptor-positive defined as 1% to 100% of tumor nuclei positive for Estrogen - - Receptor and/or Progesterone Receptor, as per ASCO/CAP Guideline 2020 - or Allred score of ≥3
• HER2-negative defined as IHC result is 0/1+ or 2+ with ISH negative as per ASCO/CAP Guideline 2018
• Diagnosed with de novo or recurrent metastatic breast cancer between January 2018 -and December 2020
• Public health system or private health system

Exclusion criteria

• Male Breast Cancer
• First-line treatment for mBC received through clinical trial

Trial design

308 participants in 1 patient group

Patients with de novo or recurrent HR-positive HER2-negative mBC

Description:

Patients diagnosed with de novo or recurrent HR-positive HER2-negative mBC from January 2018 to December 2020